论文部分内容阅读
目的 :评价口服普萘洛尔治疗婴幼儿鼻部血管瘤的临床疗效和安全性。方法 :2013年3月—2015年3月,对确诊为婴幼儿鼻部血管瘤的29例患儿采用口服普萘洛尔2.0 mg/(kg·d)治疗,分2次口服。每3~4周复诊1次,定期拍照,动态观察血管瘤的大小、质地、颜色变化,随时处理治疗过程中的不良反应,根据Achauer疗效判定标准进行疗效评价。结果:29例患儿平均口服普萘洛尔6个月。疗效Ⅰ级(差)0例,Ⅱ级(中)2例,Ⅲ级(好)9例,Ⅳ级(优)18例;2例患儿出现轻度腹泻,2例出现睡眠障碍,未发生严重不良反应。结论:口服普萘洛尔治疗婴幼儿鼻部血管瘤起效快,疗效好,不良反应轻微,可作为首选方法。
Objective: To evaluate the clinical efficacy and safety of oral propranolol in the treatment of infantile nasal hemangiomas. Methods: From March 2013 to March 2015, 29 children diagnosed as infantile nasal hemangiomas were treated with oral propranolol 2.0 mg / (kg · d) once daily for 2 times. Every 3 to 4 weeks referral 1 times, regular photographs, dynamic observation of hemangioma size, texture, color changes, at any time treatment of adverse reactions in the course of treatment, according to Achauer efficacy evaluation criteria for the evaluation of the efficacy. RESULTS: All 29 children received propranolol orally for 6 months on average. There were 2 cases with grade Ⅰ (poor), 9 cases with grade Ⅲ (good), 18 cases with grade Ⅳ (excellent), 2 cases with mild diarrhea and 2 cases with sleep disturbance Serious adverse reactions. Conclusion: Propranolol is effective in treating nasal hemangioma in infants and young children with good curative effect and mild side effects. It can be used as the preferred method.